Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

The RAINBOW trial showed that second-line ramucirumab with paclitaxel prolongs overall survival (OS) and progression-free survival (PFS) compared with placebo plus paclitaxel for treatment of advanced gastric/gastroesophageal junction cancer. Plasma samples were collected from patients during the trial and tested to identify predictive and prognostic biomarkers.

Source: European Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: E. Van Cutsem, K. Muro, D. Cunningham, G. Bodoky, A. Sobrero, S. Cascinu, J. Ajani, S.C. Oh, S.E. Al-Batran, Z.A. Wainberg, S.R. Wijayawardana, S. Melemed, D. Ferry, R.R. Hozak, A. Ohtsu, the RAINBOW Investigators Tags: Original Research Source Type: research